NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Significant Loss...
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on beha...
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.
Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Novo Nord...
Why The Hims & Hers Health Rally Has Room To Run
Hims & Hers reported 2.4 million subscribers in Q1 FY25, a 38% YoY increase from 1.74 million in Q1 FY24. Personalized treatments now make up 58% of the subscriber base, with 70% of new users choos...
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
Hims & Hers: An Excellent Subscription Business
Hims & Hers offers a high-growth, recurring subscription telehealth business with strong user and revenue growth, expanding into multiple health segments. It is the market leader in telehealth easi...
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.
Bought $40,000 of Hims & Hers (HIMS) Stock on a YOLO – Is it Time to Sell?
Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it's not for the faint of heart.
Why Hims & Hers Health (HIMS) Might be Well Poised for a Surge
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (HIMS 6.96%) may finally be succeeding in cracking the code.
Is Hims & Hers Health a Smart Buy Right Now?
When it comes to stocks that continue to beat the market, my guess is that your mind goes straight to companies leading the charge in artificial intelligence (AI). Sure, stocks such as Palantir Tec...
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
Which Telehealth Stock Should You Be Targeting?
Hims & Hers Health Inc (NYSE:HIMS) stock made waves in premarket trading, after the telehealth firebrand announced the pending acquisition of ZAVA, a European digital health platform.
Hims expands into Europe with Zava acquisition
CNBC's Brandon Gomez reports on the latest news regarding Hims.
The Bull Market is Back: 3 Stocks to Buy Now (HIMS, APP, META)
Hims & Hers Health, AppLovin and Meta Platforms all boast a litany of bullish catalysts driving their stock prices higher.
Related Companies